Alterations in estrogen signalling pathways upon acquisition of anthracycline resistance in breast tumor cells

Por Chewchuk, Simon, Guo, Baoqing, Parissenti, Amadeo Mark
Publicado no PLoS One (2017)

Role of autophagy and lysosomal drug sequestration in acquired resistance to doxorubicin in MCF-7 cells

Por Guo, Baoqing, Tam, Adam, Santi, Stacey A., Parissenti, Amadeo M.
Publicado no BMC Cancer (2016)

Role of aldo-keto reductases and other doxorubicin pharmacokinetic genes in doxorubicin resistance, DNA binding, and subcellular localization

Por Heibein, Allan D, Guo, Baoqing, Sprowl, Jason A, MacLean, David A, Parissenti, Amadeo M
Publicado em 2012

Multiple mechanisms underlying acquired resistance to taxanes in selected docetaxel-resistant MCF-7 breast cancer cells

Por Wang, Harris, Vo, The, Hajar, Ali, Li, Sarah, Chen, Xinmei, Parissenti, Amadeo M, Brindley, David N, Wang, Zhixiang
Publicado em 2014

Role of Drug Metabolism in the Cytotoxicity and Clinical Efficacy of Anthracyclines

Por Edwardson, Derek W., Narendrula, Rashmi, Chewchuk, Simon, Mispel-Beyer, Kyle, Mapletoft, Jonathan P.J., Parissenti, Amadeo M.
Publicado no Curr Drug Metab (2015)

Inhibition of protein kinase C catalytic activity by additional regions within the human protein kinase Calpha-regulatory domain lying outside of the pseudosubstrate sequence.

Por Kirwan, Angie F, Bibby, Ashley C, Mvilongo, Thierry, Riedel, Heimo, Burke, Thomas, Millis, Sherri Z, Parissenti, Amadeo M
Publicado em 2003

Role of drug transporters and drug accumulation in the temporal acquisition of drug resistance

Por Hembruff, Stacey L, Laberge, Monique L, Villeneuve, David J, Guo, Baoqing, Veitch, Zachary, Cecchetto, Melanie, Parissenti, Amadeo M
Publicado em 2008

Distinct genetic alterations occur in ovarian tumor cells selected for combined resistance to carboplatin and docetaxel

Por Armstrong, Stephen R, Narendrula, Rashmi, Guo, Baoqing, Parissenti, Amadeo M, McCallum, Katherine L, Cull, Stephanie, Lannér, Carita
Publicado em 2012

RNA disruption is associated with response to multiple classes of chemotherapy drugs in tumor cell lines

Por Narendrula, Rashmi, Mispel-Beyer, Kyle, Guo, Baoqing, Parissenti, Amadeo M., Pritzker, Laura B., Pritzker, Ken, Masilamani, Twinkle, Wang, Xiaohui, Lannér, Carita
Publicado no BMC Cancer (2016)

miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo

Por Holleman, Amy, Chung, Ivy, Olsen, Rachelle R., Kwak, Brian, Mizokami, Atsushi, Saijo, Nagahiro, Parissenti, Amadeo, Duan, Zhenfeng, Voest, Emile E., Zetter, Bruce R.
Publicado em 2011

Characterization of human septic sera induced gene expression modulation in human myocytes

Por Hussein, Shaimaa, Michael, Paul, Brabant, Danielle, Omri, Abdelwahab, Narain, Ravin, Passi, Kalpdrum, Ramana, Chilakamarti V., Parrillo, Joseph E., Kumar, Anand, Parissenti, Amadeo, Kumar, Aseem
Publicado em 2009

Alterations in tumor necrosis factor signaling pathways are associated with cytotoxicity and resistance to taxanes: a study in isogenic resistant tumor cells

Por Sprowl, Jason A, Reed, Kerry, Armstrong, Stephen R, Lanner, Carita, Guo, Baoqing, Kalatskaya, Irina, Stein, Lincoln, Hembruff, Stacey L, Tam, Adam, Parissenti, Amadeo M
Publicado em 2012

A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22

Por Trudeau, Maureen Elizabeth, Chapman, Judith-Anne W., Guo, Baoqing, Clemons, Mark J., Dent, Rebecca A., Jong, Roberta A., Kahn, Harriette J., Pritchard, Kathleen I., Han, Lei, O’Brien, Patti, Shepherd, Lois E., Parissenti, Amadeo M.
Publicado no Springerplus (2015)